:) APPI News today,,,,
still holding some.Wednesday March 1, 8:32 am Eastern Time
Company Press Release
SOURCE: Advanced Plant Pharmaceuticals, Inc.
Advanced Plant Pharmaceuticals Inc. - APPI - Purchases Allergy and Sinus line of Products
NEW YORK, March 1 /PRNewswire/ -- Advanced Plant Pharmaceuticals, Inc., (OTC Bulletin Board: APPI - news), a company that utilizes whole plants to develop all natural dietary supplements, is pleased to announce that it has signed an Asset Purchase Agreement with Dr. Leonard Bielory. The Agreement grants APPI the exclusive rights and interests to various natural and herbal Allergy and Sinus formulations developed by Dr. Bielory, Director of Allergy and Immunology and Director of the Asthma and Allergy Research Center at UMDNJ - New Jersey Medical School.
Dr. Bielory has recently completed one of the largest reviews on the topic of alternative/complimentary herbal-based treatments for the treatment of asthma and allergies (February 1999 in the Journal of Asthma). He performed a comprehensive literature search of relevant English-language papers and then analyzed them according to design, inclusion and exclusion criteria, population studied, variables tested, method of treatment (i.e. specific medicinal plants or herbal combinations), and results. The results revealed that there are indeed some herbal agents that have a positive effect on bronchodilation, pulmonary function tests, and antagonism of asthma mediators such as histamine, the production of inflammatory chemicals in the body, corticosteroid levels and clearance of mucus. In addition there was evidence for several agents to improve the symptoms seen in patients with allergic rhinitis such as specifically runny, watery nose, sneezing, and itching. However, the amount of research on these products, especially in the US, is limited and thus in concert with APPI he wishes to assist in the development and distribution of ``ethical botanicals' that is of benefit to patients suffering from these disorders with minimal side effects.
One out of four Americans suffer from Allergy or Sinus conditions. Chronic sinusitis, sinusitis that persists for at least 3 weeks, affects an estimated 32 million people in the United States. Allergic rhinitis (allergic nasal symptoms) affects more than 20% of all Americans. Overall Americans spend billions of dollars each year for medications that promise relief from Allergy and Sinus conditions.
Dr. Bielory stated, ``There is a lack of control of quantity and quality of the components in many of these herbal remedies. Yet, many have fewer side effects than current therapy. Throughout the history of medicine, drugs have been developed from many of these agents used in traditional medicine. However in concert with APPI, we will continue to investigate how some of these herbal interventions work and thus we may be able to find additional effective medicines to treat asthma and allergies as well as other common disorders such as exemplified by APPI's research and development of their cholesterol lowering agent, Lo-Chol.'
``APPI is fortunate to acquire these formulations developed by Dr. Bielory', stated David Lieberman, CEO/President of APPI. ``Dr. Bielory has believed in APPI's technology and products for quite some time, the addition of the Allergy and Sinus formulations will further enhance APPI's product line'. Mr. Lieberman further stated, ``The Allergy and Sinus market presents a gigantic opportunity for APPI. Market penetration into the Allergy and Sinus markets should be somewhat easier with the endorsement of a well respected Allergy Specialist, such as Dr. Bielory.'
APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has developed ACA, which has potential as an immunomodulator in the treatment of patients infected with the HIV virus as well as increasing energy levels in people that suffer from CFS (chronic fatigue syndrome). APPI has also developed Lo-Chol, a patented cholesterol reducing dietary supplement that in clinical studies along with a proper diet reduced total cholesterol up to 58%. APPI's ``Whole Plant' Pharmaceutical Grade Process is a trade secret. Utilization of the APPI process converts single or multiple whole plants into all-natural standardized dietary supplements. The FDA has not approved APPI's products, ACA and Lo-Chol, as nutraceuticals.
APPI has recently signed an Investment Banking Agreement with First Madison Securities, to assist APPI with its long-term capital requirements and strategic consulting services. First Madison has agreed to provide APPI with Investment Banking and advisory services, which include strategic consulting, growth and development, securities transactions, valuations, corporate finance, mergers & acquisitions, structures and capital formation, and placement agent for APPI. The Investment Banking agreement along with the purchase of a new line of products are important as APPI moves further to implement its business plan.
For more information on APPI, please visit the Company's Web site at advancedplantpharm.com.
FORWARD-LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
Contact:
Advanced Plant Pharmaceuticals, Inc.
Barry Clare, 212-695-3334
Dr. Leonard Bielory
973-972-2763
SOURCE: Advanced Plant Pharmaceuticals, Inc.
Susie |
